Elevation Oncology Inc (NASDAQ:ELEV) has a beta value of 1.29 and has seen 1.96 million shares traded in the recent trading session. The company, currently valued at $51.10M, closed the recent trade at $0.77 per share which meant it gained $0.11 on the day or 16.75% during that session. The ELEV stock price is -657.14% off its 52-week high price of $5.83 and 35.06% above the 52-week low of $0.50. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.24 million shares traded. The 3-month trading volume is 813.20K shares.
The consensus among analysts is that Elevation Oncology Inc (ELEV) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 5 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.23.
Elevation Oncology Inc (NASDAQ:ELEV) trade information
Sporting 16.75% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ELEV stock price touched $0.77 or saw a fall of -0.18%. Year-to-date, Elevation Oncology Inc shares have moved 37.75%, while the 5-day performance has seen it change 30.58%. Over the past 30 days, the shares of Elevation Oncology Inc (NASDAQ:ELEV) have changed 34.13%. Short interest in the company has seen 6.15 million shares shorted with days to cover at 8.55.
Wall Street analysts have a consensus price target for the stock at $9, which means that the shares’ value could jump 91.44% from the levels at last check today. The projected low price target is $8.0 while the price target rests at a high of $10.0. In that case, then, we find that the latest price level in today’s session is -1198.7% off the targeted high while a plunge would see the stock gain -938.96% from the levels at last check today.
Elevation Oncology Inc (ELEV) estimates and forecasts
Figures show that Elevation Oncology Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -72.22% over the past 6 months, with this year growth rate of 36.57%, compared to 16.90% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -52.56% over the past 5 years.
ELEV Dividends
Elevation Oncology Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Elevation Oncology Inc (NASDAQ:ELEV)’s Major holders
Insiders own 0.27% of the company shares, while shares held by institutions stand at 83.85% with a share float percentage of 84.08%. Investors are also buoyed by the number of investors in a company, with Elevation Oncology Inc having a total of 93.0 institutions that hold shares in the company. The top two institutional holders are LOGOS GLOBAL MANAGEMENT LP with over 3.85 million shares worth more than $10.39 million. As of 2024-06-30, LOGOS GLOBAL MANAGEMENT LP held 6.5234% of shares outstanding.
The other major institutional holder is FARALLON CAPITAL MANAGEMENT LLC, with the holding of over 3.6 million shares as of 2024-06-30. The firm’s total holdings are worth over $9.72 million and represent 6.0971% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Sep 30, 2024, the former fund manager holds about 2.77% shares in the company for having 1.64 shares of worth $1.37 million while later fund manager owns 1.32 shares of worth $1.1 million as of Oct 31, 2024, which makes it owner of about 2.23% of company’s outstanding stock.
